Diabetes, Metabolic Syndrome and Obesity (Jun 2023)
Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview
Abstract
Ozge Telci Caklili,1 Mustafa Cesur,2 Dimitri P Mikhailidis,3 Manfredi Rizzo4 1Department of Endocrinology and Metabolism, Faculty of Medicine, University of Istanbul, Istanbul, Türkiye; 2Department of Endocrinology and Metabolism, Ankara Guven University Hospital, Ankara, Türkiye; 3Department of Clinical Biochemistry and Department of Surgical Biotechnology, Division of Surgery and Interventional Science, Medical School, University College London (UCL), London, UK; 4School of Medicine, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Palermo, ItalyCorrespondence: Manfredi Rizzo, School of Medicine, Promise Department, University of Palermo, Via del Vespro 141, Palermo, 90127, Italy, Tel/Fax +39 091 655-2945, Email [email protected]: Obesity has become an epidemic and a worldwide problem and its treatment is ever-evolving. Apart from diet and exercise, medication and surgery are other options. After disappointing side effects of various obesity drugs, new treatments showed promising results. This review discusses the following anti-obesity drugs: liraglutide, semaglutide, tirzepatide, orlistat, as well as the phentermine/topiramate and bupropion/naltrexone combinations. These drugs have been approved by the Food and Drug Administration (FDA) for weight reduction except for tirzepatide which is still under evaluation. Efficacy and tolerable safety profiles of some of these drugs contribute to the management of obesity and reduce the complications associated with this chronic disease.Keywords: obesity, drugs, liraglutide, semaglutide, tirzepatide, orlistat, phentermine/topiramate, bupropion/naltrexone
